Abstract 9460: Comparing Mortality Outcomes With Different Rate Controlling Agents in Patients With Atrial Fibrillation

Abstract

Introduction: There is lack of information regarding the mortality benefits between different medications in patients with permanent atrial fibrillation (AF). Purpose: We aimed to identify if there is any difference in mortality between the use of different rate controlling medications in patients with permanent AF. Methods: We identified patients with permanent AF without history of heart failure (HF) by using the TriNetX research database which provides information from electronic medical records from several health care institutions primarily based in the United States. Patients were divided in 4 cohorts, those taking metoprolol, diltiazem, carvedilol, or atenolol. Propensity score matching (PSM) was used to equilibrate the cohorts based on past medical history and medications. The cohorts were compared amongst each other after PSM. Results: There was no difference in mortality, emergency room visits, or hospitalizations with the use of different rate-controlling medications. Conclusion: This study suggests that there is no difference in mortality with the use of metoprolol, carvedilol, atenolol, or diltiazem in patients with permanent AF without history of HF.